Windward Bio Group AG will present at the Jefferies London Global Healthcare Conference on November 18, 2026.
Quiver AI Summary
Windward Bio Group AG, a clinical-stage biotechnology company focused on developing ultra-long-acting antibody treatments for serious respiratory and dermatologic diseases, announced that its management will present at the Jefferies London Global Healthcare Conference on November 18, 2026, at 8:30 a.m. GMT. The event will be accessible through a live and archived webcast on the company's website. Windward is currently advancing two main product candidates: WIN378, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) in studies for severe uncontrolled asthma and COPD, and WIN027, a bispecific antibody aimed at TSLP and interleukin-13, which is in a Phase 1 study.
Potential Positives
- Windward Bio Group AG is actively participating in a prominent healthcare conference, showcasing its commitment to transparency and engagement with investors and the healthcare community.
- The presentations at the Jefferies London Global Healthcare Conference provide an opportunity to highlight their innovative product candidates, potentially attracting interest and investment.
- Windward's lead product candidate, WIN378, is undergoing evaluation in critical Phase 2/3 studies for severe uncontrolled asthma, indicating progress in their clinical development pipeline.
- The company's second product candidate, WIN027, is already in Phase 1 studies, demonstrating ongoing advancements in their research and development efforts in treating serious respiratory and dermatologic diseases.
Potential Negatives
- Company is presenting at a healthcare conference, which could indicate that it is still in early stages of development and seeking broader investor interest.
- Despite having a pipeline of products, the company is still classified as a clinical-stage biotechnology firm, suggesting it has not yet brought any products to market.
- Specifics about product efficacy or safety data from ongoing studies are not provided, which may raise concerns about the progress and viability of their product candidates.
FAQ
What is Windward Bio Group AG?
Windward Bio Group AG is a clinical-stage biotechnology company focused on developing ultra-long-acting antibody medicines for serious respiratory and dermatologic diseases.
When will Windward present at the Jefferies London Global Healthcare Conference?
Windward will present at the conference on Wednesday, November 18, 2026, at 8:30 a.m. GMT.
How can I access the webcast of Windward's presentation?
A live and archived webcast of the presentation will be available on the News & Events page in the Investors section of Windward's website.
What diseases do Windward's products target?
Windward's products target serious diseases including asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis.
What are the lead product candidates of Windward?
Windward's lead product candidates include WIN378, targeting TSLP in asthma and COPD, and WIN027, a bispecific antibody in Phase 1 studies.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
Full Release
BASEL, Switzerland, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Windward Bio Group AG ("Windward") (Nasdaq: WWB), a clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, today announced that members of management will present at the Jefferies London Global Healthcare Conference on Wednesday, November 18, 2026, at 8:30 a.m.GMT.
A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Windward Bio website.
About Windward Bio Group AG
Windward (Nasdaq: WWB) is a global, clinical-stage biotechnology company developing ultra-long-acting antibody medicines for patients with serious respiratory and dermatologic diseases, including asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis. Its lead product candidate, WIN378, is a fully human monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and is being evaluated in the POLARIS-1 Phase 2/3 study in severe uncontrolled asthma and the SIRIUS Phase 2 study in COPD. Windward’s second product candidate, WIN027, is an ultra-long-acting bispecific antibody targeting TSLP and interleukin-13 (IL-13) and is currently in a Phase 1 healthy volunteer study.
For media and investor inquiries:
Noel Kurdi
SVP, Investor Relations and Communications
Windward Bio
[email protected]